Progressively impaired proteasomal capacity during terminal plasma cell differentiation

EMBO Journal

Volumn 25, Issue 5, 2006, Pages 1104-1113

  Cenci, Simone ^a,b   Mezghrani, Alexandre ^a,g   Cascio, Paolo ^c   Bianchi, Giada ^a,b   Cerruti, Fulvia ^c   Fra, Anna ^d   Lelouard, Hugues ^e   Masciarelli, Silvia ^a,b   Mattioli, Laura ^f   Oliva, Laura ^a   Orsi, Andrea ^a,b   Pasqualetto, Elena ^a   Pierre, Philippe ^e   Ruffato, Elena ^a   Tagliavacca, Luigina ^a   Sitia, Roberto ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^f UNIVERSITY OF GENOA   (Italy)

^g INSTITUTE OF HUMAN GENETICS   (France)

Author keywords

Apoptosis; Myeloma; Plasma cell; Proteasome; Unfolded protein response

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN MU CHAIN; POLYUBIQUITIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN; PROTEIN BAX; PROTEIN XBP1S; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; I-KAPPA B PROTEINS; IMMUNOGLOBULIN M; IMMUNOGLOBULIN MU-CHAINS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NUCLEAR PROTEINS; PLASMA CELLS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; SPLEEN; UBIQUITIN;

ANIMALIA;

EID: 33644871448     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/sj.emboj.7601009     Document Type: Article

References (59)

1. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360
2. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S (1994) The CD40 antigen and its ligand. Annu Rev Immunol 12: 881-922
3. Bedner E, Li X, Gorczyca W, Melamed MR, Darzynkiewicz Z (1999) Analysis of apoptosis by laser scanning cytometry. Cytometry 35: 181-195
4. Borner C (2003) The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 39: 615-647
5. Breckenridge DG, Germain M, Mathai JP, Nguyen M, Shore GC (2003) Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22: 8608-8618
6. Brewer JW, Hendershot LM (2005) Building an antibody factory: a job for the unfolded protein response. Nat Immunol 6: 23-29
7. Calame KL, Lin KI, Tunyaplin C (2003) Regulatory mechanisms that determine the development and function of plasma cells. Annu. Rev Immunol 21: 205-230
8. Cals MM, Guenzi S, Carelli S, Simmen T, Sparvoli A, Sitia R (1996) IgM polymerization inhibits the Golgi-mediated processing of the mu-chain carboxy-terminal glycans. Mol Immunol 33: 15-24
9. Cascio P, Hilton C, Kisselev AF, Rock KL, Goldberg AL (2001) 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J 20: 2357-2366
10. Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG (2000) Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 18: 538-543
11. Donjerkovic D, Scott DW (2000) Activation-induced cell death in B lymphocytes. Cell Res 10: 179-192
12. Eriksson KK, Vago R, Calanca V, Galli C, Paganetti P, Molinari M (2004) EDEM contributes to maintenance of protein folding efficiency and secretory capacity. J Biol Chem 279: 44600-44605
13. Fagioli C, Mezghrani A, Sitia R (2001) Reduction of interchain disulfide bonds precedes the dislocation of Ig-mu chains from the endoplasmic reticulum to the cytosol for proteasomal degradation. J Biol Chem 276: 40962-40967
14. Fagioli C, Sitia R (2001) Glycoprotein quality control in the endoplasmic reticulum. Mannose trimming by endoplasmic reticulum mannosidase I times the proteasomal degradation of unassembled immunoglobulin subunits. J Biol Chem 276: 12885-12892
15. Fra AM, Fagioli C, Finazzi D, Sitia R, Alberini CM (1993) Quality control of ER synthesized proteins: an exposed thiol group as a three-way switch mediating assembly, retention and degradation. EMBO J 12: 4755-4761
16. Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899
17. Goldberg AL, Rock K (2002) Not just research tools - proteasome inhibitors offer therapeutic promise. Nat Med 8: 338-340
18. Hase H, Kanno Y, Kojima H, Morimoto C, Okumura K, Kobata T (2002) CD27 and CD40 inhibit p53-independent mitochondrial pathways in apoptosis of B cells induced by B cell receptor ligation. J Biol Chem 277: 46950-46958
19. Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937
20. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076
21. Hideshima T, Richardson PG, Anderson KC (2003) Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol 7: 191-204
22. Ho F, Lortan JE, MacLennan IC, Khan M (1986) Distinct short-lived and long-lived antibody-producing cell populations. Eur J Immunol 16: 1297-1301
23. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, Radbruch A, Hiepe F, Manz RA (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199: 1577-1584
24. Iwakoshi NN, Lee AH, Glimcher LH (2003a) The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol Rev 194: 29-38
25. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH (2003b) Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 4: 321-329
26. Johnson-Leger C, Christenson JR, Holman M, Klaus GG (1998) Evidence for a critical role for IL-2 in CD40-mediated activation of naive B cells by primary CD4T cells. J Immunol 161: 4618-4626
27. Kasibhatla S, Tseng B (2003) Why target apoptosis in cancer treatment? Mol Cancer Ther 2: 573-580
28. Kopito RR, Sitia R (2000) Aggresomes and Russell bodies. EMBO Rep 1: 225-231
29. Kroesen BJ, Jacobs S, Pettus BJ, Sietsma H, Kok JW, Hannun YA, de Leij LF (2003) BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome. J Biol Chem 278: 14723-14731
30. Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2: 175-187
31. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF (2001) Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470
32. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 100: 9946-9951
33. Lelouard H, Gatti E, Cappello F, Gresser O, Camosseto V, Pierre P (2002) Transient aggregation of ubiquitinated proteins during dendritic cell maturation. Nature 417: 177-182
34. Li B, Dou QP (2000) Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97: 3850-3855
35. Lin L, DeMartino GN, Greene WC (1998) Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome. Cell 92: 819-828
36. Lindsten K, Menendez-Benito V, Masucci MG, Dantuma NP (2003) A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol 21: 897-902
37. Ma Y, Hendershot LM (2003) The stressful road to antibody secretion. Nat Immunol 4: 310-311
38. Macagno A, Kuehn L, de Giuli R, Groettrup M (2001) Pronounced up-regulation of the PA28alpha/beta proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation. Eur J Immunol 31: 3271-3280
39. Mancini R, Fagioli C, Fra AM, Maggioni C, Sitia R (2000) Degradation of unassembled soluble Ig subunits by cytosolic proteasomes: evidence that retrotranslocation and degradation are coupled events. FASEB J 14: 769-778
40. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A (2002) Humoral immunity and long-lived plasma cells. Curr Opin Immunol 14: 517-521
41. Marsden VS, Strasser A (2003) Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu Rev Immunol 21: 71-105
42. Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, Kruger E (2003) Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes. J Biol Chem 278: 21517-21525
43. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96: 10403-10408
44. Ossendorp F, Fu N, Camps M, Granucci F, Gobin SJ, van den Elsen PJ, Schuurhuis D, Adema GJ, Lipford GB, Chiba T, Sijts A, Kloetzel PM, Ricciardi-Castagnoli P, Melief CJ (2005) Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J Immunol 174: 7815-7822
45. Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, Hornung V, Jahrsdorfer B, Giese T, Endres S, Hartmann G (2004) Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 103: 3058-3064
46. Rabinovich E, Kerem A, Frohlich KU, Diamant N, Bar-Nun S (2002) AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. Mol Cell Biol 22: 626-634
47. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravallese EM, Friend D, Grusby MJ, Alt F, Glimcher LH (2001) Plasma cell differentiation requires the transcription factor XBP-1. Nature 412: 300-307
48. Rock KL, Goldberg AL (1999) Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17: 739-779
49. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, Yu X, Yang L, Tan BK, Rosenwald A, Hurt EM, Petroulakis E, Sonenberg N, Yewdell JW, Calame K, Glimcher LH, Staudt LM (2004) XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21: 81-93
50. Sitia R, Braakman I (2003) Quality control in the endoplasmic reticulum protein factory. Nature 426: 891-894
51. Sitia R, Neuberger M, Alberini C, Bet P, Fra A, Valetti C, Williams G, Milstein C (1990) Developmental regulation of IgM secretion: the role of the carboxy-terminal cysteine. Cell 60: 781-790
52. Sitia R, Neuberger MS, Milstein C (1987) Regulation of membrane IgM expression in secretory B cells: translational and post-translational events. EMBO J 6: 3969-3977
53. Sriburi R, Jackowski S, Mori K, Brewer JW (2004) XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J Cell Biol 167: 35-41
54. Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM (2004) Caspase activation inhibits proteasome function during apoptosis. Mol Cell 14: 81-93
55. Symeonidis A, Kouraklis-Symeonidis A, Grouzi E, Zolota V, Melachrinou M, Kourea K, Fragopanagou E, Giannakoulasa N, Seimeni U, Tiniakou M, Matsouka P, Zoumbos N (2002) Determination of plasma cell secreting potential as an index of maturity of myelomatous cells and a strong prognostic factor. Leukemia Lymphoma 43: 1605-1512
56. Tirosh B, Iwakoshi NN, Glimcher LH, Ploegh HL (2005) XBP-1 specifically promotes IgM synthesis and secretion, but is dispensable for degradation of glycoproteins in primary B cells. J Exp Med 202: 505-516
57. van Anken E, Romijn EP, Maggioni C, Mezghrani A, Sitia R, Braakman I, Heck AJ (2003) Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity 18: 243-253
58. Yoshida H, Matsui T, Hosokawa N, Kaufman RJ, Nagata K, Mori K (2003) A time-dependent phase shift in the mammalian unfolded protein response. Dev Cell 4: 265-271
59. Zavrski I, Naujokat C, Niemoller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K, Sezer O (2003) Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 129: 383-391